153 related articles for article (PubMed ID: 17223739)
1. Ii-Key/MHC class II epitope hybrids: a strategy that enhances MHC class II epitope loading to create more potent peptide vaccines.
Kallinteris NL; Lu X; Blackwell CE; von Hofe E; Humphreys RE; Xu M
Expert Opin Biol Ther; 2006 Dec; 6(12):1311-21. PubMed ID: 17223739
[TBL] [Abstract][Full Text] [Related]
2. CD4+ T-cell activation for immunotherapy of malignancies using Ii-Key/MHC class II epitope hybrid vaccines.
Xu M; Kallinteris NL; von Hofe E
Vaccine; 2012 Apr; 30(18):2805-10. PubMed ID: 22386748
[TBL] [Abstract][Full Text] [Related]
3. Ii-Key/HER-2/neu MHC class-II antigenic epitope vaccine peptide for breast cancer.
Gillogly ME; Kallinteris NL; Xu M; Gulfo JV; Humphreys RE; Murray JL
Cancer Immunol Immunother; 2004 Jun; 53(6):490-6. PubMed ID: 14740174
[TBL] [Abstract][Full Text] [Related]
4. Ii-Key/MHC class II epitope hybrid peptide vaccines for HIV.
Kallinteris NL; Lu X; Wu S; Hu H; Li Y; Gulfo JV; Humphreys RE; Xu M
Vaccine; 2003 Oct; 21(27-30):4128-32. PubMed ID: 14505892
[TBL] [Abstract][Full Text] [Related]
5. Invariant chain-peptide fusion vaccine using HER-2/neu.
Perez SA; Peoples GE; Papamichail M; Baxevanis CN
Methods Mol Biol; 2014; 1139():321-36. PubMed ID: 24619690
[TBL] [Abstract][Full Text] [Related]
6. MHC class II-associated invariant chain peptide replacement by T cell epitopes: engineered invariant chain as a vehicle for directed and enhanced MHC class II antigen processing and presentation.
Malcherek G; Wirblich C; Willcox N; Rammensee HG; Trowsdale J; Melms A
Eur J Immunol; 1998 May; 28(5):1524-33. PubMed ID: 9603457
[TBL] [Abstract][Full Text] [Related]
7. Enhanced CD4+ T-cell response in DR4-transgenic mice to a hybrid peptide linking the Ii-Key segment of the invariant chain to the melanoma gp100(48-58) MHC class II epitope.
Kallinteris NL; Wu S; Lu X; Humphreys RE; von Hofe E; Xu M
J Immunother; 2005; 28(4):352-8. PubMed ID: 16000953
[TBL] [Abstract][Full Text] [Related]
8. Invariant chains with the class II binding site replaced by a sequence from influenza virus matrix protein constrain low-affinity sequences to MHC II presentation.
Carstens C; Newman DK; Bohlen H; König A; Koch N
Int Immunol; 2000 Nov; 12(11):1561-8. PubMed ID: 11058576
[TBL] [Abstract][Full Text] [Related]
9. MHC class II loading of high or low affinity peptides directed by Ii/peptide fusion constructs: implications for T cell activation.
Gregers TF; Fleckenstein B; Vartdal F; Roepstorff P; Bakke O; Sandlie I
Int Immunol; 2003 Nov; 15(11):1291-9. PubMed ID: 14565927
[TBL] [Abstract][Full Text] [Related]
10. Presentation of endogenously synthesized MHC class II-restricted epitopes by MHC class II cancer vaccines is independent of transporter associated with Ag processing and the proteasome.
Dissanayake SK; Tuera N; Ostrand-Rosenberg S
J Immunol; 2005 Feb; 174(4):1811-9. PubMed ID: 15699107
[TBL] [Abstract][Full Text] [Related]
11. Increasing the potency of MHC class II-presented epitopes by linkage to Ii-Key peptide.
Humphreys RE; Adams S; Koldzic G; Nedelescu B; von Hofe E; Xu M
Vaccine; 2000 Jun; 18(24):2693-7. PubMed ID: 10781856
[TBL] [Abstract][Full Text] [Related]
12. Ii-Key/MHC class II epitope peptides as helper T cell vaccines for cancer and infectious disease.
Kallinteris NL; Powell D; Blackwell CE; Kim M; Lu X; Wu S; Humphreys RE; Xu M; von Hofe E
Front Biosci; 2006 Jan; 11():46-58. PubMed ID: 16146713
[TBL] [Abstract][Full Text] [Related]
13. The efficacy of chimeric vaccines constructed with PEP-1 and Ii-Key linking to a hybrid epitope from heterologous viruses.
Liu XL; Shan WJ; Xu SS; Zhang JJ; Xu FZ; Xia SL; Dai Y
Biologicals; 2015 Sep; 43(5):377-82. PubMed ID: 26153399
[TBL] [Abstract][Full Text] [Related]
14. Superior tumor protection induced by a cellular vaccine carrying a tumor-specific T helper epitope by genetic exchange of the class II-associated invariant chain peptide.
van Bergen J; Camps M; Offringa R; Melief CJ; Ossendorp F; Koning F
Cancer Res; 2000 Nov; 60(22):6427-33. PubMed ID: 11103809
[TBL] [Abstract][Full Text] [Related]
15. Linkage of Ii-Key segment to gp100(46-58) epitope enhances the production of epitope-specific antibodies.
Kallinteris NL; Wu S; Lu X; von Hofe E; Humphreys RE; Xu M
Vaccine; 2005 Mar; 23(17-18):2336-8. PubMed ID: 15755623
[TBL] [Abstract][Full Text] [Related]
16. T cell recognition of major histocompatibility complex class II complexes with invariant chain processing intermediates.
Morkowski S; Goldrath AW; Eastman S; Ramachandra L; Freed DC; Whiteley P; Rudensky AYu
J Exp Med; 1995 Nov; 182(5):1403-13. PubMed ID: 7595211
[TBL] [Abstract][Full Text] [Related]
17. Boosting immune response with the invariant chain segments via association with non-peptide binding region of major histocompatibility complex class II molecules.
Chen F; Meng F; Pan L; Xu F; Liu X; Yu W
BMC Immunol; 2012 Sep; 13():55. PubMed ID: 23016601
[TBL] [Abstract][Full Text] [Related]
18. Efficient presentation of known HLA class II-restricted MAGE-A3 epitopes by dendritic cells electroporated with messenger RNA encoding an invariant chain with genetic exchange of class II-associated invariant chain peptide.
Bonehill A; Heirman C; Tuyaerts S; Michiels A; Zhang Y; van der Bruggen P; Thielemans K
Cancer Res; 2003 Sep; 63(17):5587-94. PubMed ID: 14500399
[TBL] [Abstract][Full Text] [Related]
19. Ii-Key/HPV16 E7 hybrid peptide immunotherapy for HPV16+ cancers.
Xu M; Lu X; Sposato M; Zinckgraf JW; Wu S; von Hofe E
Vaccine; 2009 Jul; 27(34):4641-7. PubMed ID: 19520206
[TBL] [Abstract][Full Text] [Related]
20. MHC class II allosteric site drugs: new immunotherapeutics for malignant, infectious and autoimmune diseases.
Xu M; Li J; Gulfo JV; Von Hofe E; Humphreys RE
Scand J Immunol; 2001; 54(1-2):39-44. PubMed ID: 11439146
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
